Finally, the APIM
was utilized to explore possible actor and partner effects across the study variables, as noted in Table 4.
An over-time APIM without measurement of the partner effects (due to the couples-based discrepancy score) was conducted to analyze the third research question of interest: the impact of couple sexual desire discrepancy on quality of the sexual experience at the event level (see Figure 2).
Over-time APIM fixed actor and partner effects predicting quality of sexual experience with individual sexual desire Standard Estimate Error DF t Women Actor Effect .
Therapeutics AS Kadmon Pharmaceuticals, LLC centrose llc Immodulon Therapeutics Ltd.
The investment is led by Norsk Innovasjonskapital III AS, a leading Norwegian VC firm in syndication with existing APIM investors, Sarsia Seed (Bergen, Norway), Birk Venture and Ro Invest (Oslo, Norway).
Konstantinos Alevizopoulos, CEO of APIM Therapeutics: "We are delighted to have secured this additional funding in APIM Therapeutics which will allow for further preclinical development of our novel therapeutic concept".
The follow-up investment is provided by Birk Venture and Ro Invest, two early stage investment companies located in Oslo, Norway, and Sarsia Seed, a seed stage investor that has already led two investment transactions in APIM Therapeutics.
Konstantinos Alevizopoulos, CEO of APIM Therapeutics:" We are delighted to have secured this additional funding in APIM Therapeutics which will allow for the further development of our novel therapeutic concept towards first-in-man clinical trials".
Their equal enthusiasm for the company and its exceptional offering, further consolidates our belief in APIM Therapeutics.
TRONDHEIM, Norway, March 21, 2011 /PRNewswire/ -- APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.
This is the second seed investment by Sarsia Seed to APIM Therapeutics to-date.
Konstantinos Alevizopoulos, CEO of APIM Therapeutics:"We are delighted that Sarsia Seed has provided this follow-up funding, which is a vote of confidence in the company's results so far.